Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...

RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Shares of NASDAQ KRRO opened at $77.00 on Thursday. Korro Bio has a 12-month low of $9.15 and a 12-month high of $98.00. The stock has a fifty day moving average price of $40.45 and a 200 day ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...